BioSpace News Archive

Drug Development

Celgene Corporation Announces Initial Clinical Data from Ongoing Phase 1/2 Evolve Trial with Anti-BCMA CAR T Therapy JCARH125 in Relapsed/Refractory Multiple Myeloma at ASH 2018

82% overall response rate observed in heavily pre-treated patients

December 3, 2018
·
3 min read
Drug Development

Kite Announces Updated Data From ZUMA-3 Study of KTE-X19 in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Ongoing Phase 1/2 Study Continues to Demonstrate High Rates of Response to a Single Infusion of KTE-X19 in a Patient Population with Limited Treatment Options

December 3, 2018
·
5 min read
Drug Development

Results Presented from Primary Analysis of the Phase III HAVEN 2 Study with Chugai’s HEMLIBRA® for Children with Hemophilia A with Inhibitors at the American Society of Hematology 2018

Chugai Pharmaceutical Co., Ltd. announced that the primary analysis of the phase III HAVEN 2 study (NCT02795767), evaluating hemophilia A treatment HEMLIBRA® in children with hemophilia A with factor VIII inhibitors, was reported in an Oral Presentation at the 60th American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 1 to 4 2018.

December 3, 2018
·
6 min read
Business

Mitsubishi Electric and the University of Tokyo Reveal New Mechanism for Enhancing Reliability of SiC Power Semiconductor Devices

Mitsubishi Electric Corporation and the University of Tokyo announced today what they believe to be an all-new mechanism for enhancing the reliability of silicon carbide (SiC) power semiconductor devices in power electronics systems.

December 3, 2018
·
2 min read
Drug Development

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent β-Thalassemia at 60th Annual Meeting of the American Society of Hematology

First presentation of data from patients with a β0/β0 genotype and a pediatric patient treated with LentiGlobin in Phase 3 Northstar-3 study both have stopped chronic blood transfusions

December 3, 2018
·
9 min read
Drug Development

bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology

LentiGlobin treatment-derived hemoglobin HbAT87Q equals or exceeds sickling hemoglobin (HbS) levels in Group C patients at six months post treatment

December 3, 2018
·
8 min read
Drug Development

Data Presented at ASH Support Emapalumab as an Innovative, Targeted Therapeutic Option for Primary HLH

Swedish Orphan Biovitrum AB (publ) (Sobi™) and Novimmune SA are presenting data from the pivotal phase 2/3 clinical study of emapalumab-lzsg in primary haemophagocytic lymphohistiocytosis (HLH) as part of the late-breaking abstract session at the 60th Annual Meeting of the American Society of Hematology (ASH), taking place 1-4 December 2018, in San Diego.

December 3, 2018
·
7 min read
Drug Development

Nordic Nanovector: Additional Preclinical Studies With CD37-targeting Radioimmunotherapies for B-cell Malignancies Presented at ASH

Nordic Nanovector ASA notes that two new poster presentations from preclinical studies with CD37-targeting radioimmunotherapies were made at the 60th American Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018 in San Diego, CA, USA).

December 3, 2018
·
5 min read
Drug Development

Freeline Presents Data on AAV-based Gene Therapy for Haemophilia B at the 60th ASH Annual Meeting

Freeline, a clinical stage gene therapy company focused on providing life-changing curative treatments for chronic diseases, on December 3rd presented initial results from the ongoing B-AMAZE Phase 1/2 trial investigating FLT180a for Haemophilia B.

December 3, 2018
·
3 min read
Regulated information – Inside information argenx enters exclusive global collaboration and license agreement with  Cilag GmbH International, an affiliate of Janssen, for cusatuzumab (ARGX-110)

argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced an exclusive, global collaboration and license agreement for cusatuzumab (ARGX-110)

December 3, 2018
·
6 min read